Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01983085
Other study ID # EDX 120
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date September 2013
Est. completion date May 2014

Study information

Verified date April 2021
Source Edixomed Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a study to assess the safety and efficacy of a nitric oxide (NOx) generating dressing on superficial partial thickness (SPT) wounds. Nitric oxide has a range of effects on the body including vasodilation and angiogenesis. It is also a potent antimicrobial. This 160 patient, randomised, controlled clinical study will assess the ability of a simple 2 part, NOx generating dressing to improve healing in SPT burn wounds and SPT skin graft donor site wounds compared to standard of care.


Description:

This is a clinical study of a new wound dressing for superficial partial thickness (SPT) wounds. The dressing consists of 2 stable layers that when placed together release Nitric Oxide. In preclinical studies NOx delivery has caused significant vasodilation, angiogenesis and demonstrated potent anti-microbial activity. This is a multi-centre, 160 patient, randomised, controlled study. There are 2 arms to the study. 80 patients will have treatment applied to a SPT burn wound and 80 patients will have treatment applied to a SPT graft donor site wound. The controls will be intra-individual. Each patient will have their wound divided into 2, half of the wound being treated with the NOx dressing, the other half treated with standard of care. The positioning of the dressings will be randomised. The NOx dressing will be changed at least every 2 days and the standard of care changed according to normal clinical practice and patients will be treated until the wound is healed. The study will evaluate: - The size of the wound - Eepithelialisation - Trans-epidermal water loss - Infection status. There will be 3 and 12 month follow up with assessment of scarring.


Recruitment information / eligibility

Status Terminated
Enrollment 13
Est. completion date May 2014
Est. primary completion date March 2014
Accepts healthy volunteers No
Gender All
Age group 1 Year and older
Eligibility Inclusion Criteria: - Patients who have a Superficial Partial Thickness wound (2a) either from a thermal injury or from a skin graft donor site under the care of St. Andrews service, within the recruitment timeline. - Wound area to be treated in study must be less than 5% of total body surface area (TBSA). - Patients aged over 12 months and up to and including 80 years old. - Informed Consent Exclusion Criteria: - Any inclusion criteria not met - Unwilling to consent to investigation/ unable to provide consent - Wounds deeper than superficial partial thickness (2b, 3 and 4) - Chemical /Electrical burns - Already having received silver sulfadiazine - Disease that could affect wound healing - Previous participation in the study - Females who are pregnant or breast-feeding. - Relative, spouse or employee of the investigational site - Known multiple allergic disorders - Skin disorders - Facial burns - Patients who have taken part in any investigational studies within the last 30 days prior to participation.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
NOx dressing
The NOx dressing should be changed at least every 2 days.
Standard of Care
Dressing changed as per normal clinical practice

Locations

Country Name City State
United Kingdom St Andrew's Centre for Plastic Surgery and Burns, Broomfield Hospital Chelmsford Essex
United Kingdom Canniesburn Regional Plastic Surgery and Burns Unit, Glasgow Royal Infirmary, Glasgow

Sponsors (1)

Lead Sponsor Collaborator
Edixomed Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Average number of days until healing (defined as 95% epithelisation) in SPT wounds treated with conventional Mepitel® dressing vs. investigational nitric oxide generating gel dressing From randomisation and first application of the dressing, patients are assessed every 2 days until 95% epithelialisation occurs
Secondary Assessment of healing by blinded evaluation of photographs Every 2 days from baseline until 95% epithelialisation occurs
Secondary Cosmetic Outcomes measured using both the Vancouver Scar Scale and the Patient Observer Scar Assessment Scale 3 and 12 months post healing
Secondary Colonisation of wounds Wound swabs will be taken at every patient visit, every 2 days, until 95% epithelialisation occurs. Baseline and every 2 days therafter until 95% epithelialisation occurs
Secondary Tolerance and safety of the dressing Assessment of reported adverse events Baseline and every 2 days thereafter
See also
  Status Clinical Trial Phase
Terminated NCT04601532 - Superficial Partial-Thickness Burn Study Phase 4